Medicenna Therapeutics Corp.
MDNA.TO
TSX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -20.87% | -24.57% | -24.00% | -28.36% | 2.49% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.14% | 15.67% | 16.25% | 5.74% | 8.19% |
| Operating Income | -17.14% | -15.67% | -16.25% | -5.74% | -8.19% |
| Income Before Tax | 52.31% | 49.25% | 51.06% | 54.48% | -72.86% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 52.31% | 49.25% | 51.06% | 54.48% | -72.86% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 52.31% | 49.25% | 51.06% | 54.48% | -72.86% |
| EBIT | -17.14% | -15.67% | -16.25% | -5.74% | -8.19% |
| EBITDA | -17.18% | -15.51% | -16.01% | -5.56% | -8.01% |
| EPS Basic | 58.51% | 55.64% | 56.69% | 58.43% | -65.49% |
| Normalized Basic EPS | 58.46% | 55.61% | 56.68% | 58.38% | -65.72% |
| EPS Diluted | 58.51% | 55.64% | 56.69% | 58.43% | -65.49% |
| Normalized Diluted EPS | 58.46% | 55.61% | 56.68% | 58.38% | -65.72% |
| Average Basic Shares Outstanding | 9.87% | 11.18% | 11.69% | 10.09% | 7.06% |
| Average Diluted Shares Outstanding | 9.87% | 11.18% | 11.69% | 10.09% | 7.06% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |